What does that drug do? Focus on Injectable Dulaglutide

Possible doses: Injectable dulaglutide is a glucose lowering drug that is taken once weekly. The weekly dose for the treatment of type 2 diabetes ranges between 0.75 mg to 4.5 mg.

What it does: In addition to lowering glucose, randomized controlled trials have clearly shown that injectable dulaglutide reduces the occurrence of strokes, heart attacks, death from heart disease and kidney damage.

How it works: Injectable dulaglutide lowers glucose by increasing the amount of insulin made by the pancreas whenever the glucose level is elevated. It does not increase insulin secretion by the pancreas when the glucose level is normal or low. This drug also causes weight loss, reduces appetite, and can lower blood pressure. Exactly how it reduces strokes, heart disease, kidney disease and death is not clearly understood.

Side effects: The drug acts on the brain and the intestines (the gut) as well as on the pancreas. Many people report that their interest in certain types of food changes along with a reduced appetite. The drug also slows how fast the stomach empties, so many people report feeling full quickly after eating. This is less of a problem if people eat their meals slower than usual when starting this drug. Some people report nausea and rarely vomiting. Dulaglutide may also cause diarrhea or constipation which gets better in most people within two months time. Although the drug itself does not cause hypoglycemia, it does increase the effectiveness of the drugs that can cause low blood sugar levels (i.e., hypoglycemia) – insulin and sulfonylurea drugs like gliclazide or glyburide. Therefore, when starting dulaglutide, many patients are advised to reduce any insulin or sulfonylurea drugs that they may also be taking.

Bottom line: Injectable dulaglutide is a safe and effective treatment for diabetes that also reduces strokes, heart disease and kidney disease. In addition, many people lose weight. Note that it is also prescribed to reduce weight and serious health outcomes in people without diabetes. It is not approved for people with type 1 diabetes.

About the author

Hertzel Gerstein, Endocrinologist

Hertzel is an endocrinologist and professor at McMaster University who is in high demand as a speaker, advocate, and educator on diabetes-related topics. His research focuses on using large, international randomized trials to identify and test new ways of preventing type 2 diabetes, reducing serious health outcomes like strokes and death, and achieving type 2 diabetes remissions.